...well, at least our past management had the wisdom to go down the RCT route for GvHD. An MSB approval would have had a nice halo effect for CYP and other stem cell companies, just as the April Gamida FDA approval had very small positive halo effects therein. Today a sad day for GvHD sufferers as well as a painful day for MSB investors.
CYP's approvals will be in knee OA far before any progress elsewhere, with P3 recruitment end of this year.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.15M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.5¢ | 16.0¢ | $60.94K | 379.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 158709 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 35334 | 4 |
View Market Depth
| Last trade - 14.38pm 25/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |